全文获取类型
收费全文 | 106934篇 |
免费 | 9307篇 |
国内免费 | 670篇 |
专业分类
耳鼻咽喉 | 1749篇 |
儿科学 | 2700篇 |
妇产科学 | 2229篇 |
基础医学 | 12056篇 |
口腔科学 | 2292篇 |
临床医学 | 11640篇 |
内科学 | 23555篇 |
皮肤病学 | 1743篇 |
神经病学 | 9051篇 |
特种医学 | 3767篇 |
外国民族医学 | 2篇 |
外科学 | 18278篇 |
综合类 | 1437篇 |
现状与发展 | 3篇 |
一般理论 | 143篇 |
预防医学 | 9015篇 |
眼科学 | 2696篇 |
药学 | 7016篇 |
中国医学 | 167篇 |
肿瘤学 | 7372篇 |
出版年
2023年 | 1019篇 |
2022年 | 1057篇 |
2021年 | 2487篇 |
2020年 | 2032篇 |
2019年 | 2162篇 |
2018年 | 3011篇 |
2017年 | 2240篇 |
2016年 | 2514篇 |
2015年 | 2771篇 |
2014年 | 4128篇 |
2013年 | 5723篇 |
2012年 | 6825篇 |
2011年 | 7192篇 |
2010年 | 4416篇 |
2009年 | 4380篇 |
2008年 | 6645篇 |
2007年 | 6670篇 |
2006年 | 6394篇 |
2005年 | 6385篇 |
2004年 | 5944篇 |
2003年 | 5336篇 |
2002年 | 5171篇 |
2001年 | 1080篇 |
2000年 | 890篇 |
1999年 | 1099篇 |
1998年 | 1292篇 |
1997年 | 1109篇 |
1996年 | 1033篇 |
1995年 | 930篇 |
1994年 | 798篇 |
1993年 | 698篇 |
1992年 | 739篇 |
1991年 | 706篇 |
1990年 | 548篇 |
1989年 | 623篇 |
1988年 | 552篇 |
1987年 | 487篇 |
1986年 | 473篇 |
1985年 | 540篇 |
1984年 | 567篇 |
1983年 | 518篇 |
1982年 | 670篇 |
1981年 | 534篇 |
1980年 | 571篇 |
1979年 | 347篇 |
1978年 | 386篇 |
1977年 | 382篇 |
1976年 | 302篇 |
1975年 | 343篇 |
1974年 | 274篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
951.
952.
953.
Carolin Lepa Sascha Hoppe Antje Stber Boris V. Skryabin Laura Katharina Sievers Barbara Heitplatz Giuliano Ciarimboli Ute Neugebauer Maja T. Lindenmeyer Clemens D. Cohen Hannes C.A. Drexler Peter Boor Thomas Weide Hermann Pavenstdt Britta George 《Journal of the American Society of Nephrology : JASN》2021,32(2):357
BackgroundInjury to kidney podocytes often results in chronic glomerular disease and consecutive nephron malfunction. For most glomerular diseases, targeted therapies are lacking. Thus, it is important to identify novel signaling pathways contributing to glomerular disease. Neurotrophic tyrosine kinase receptor 3 (TrkC) is expressed in podocytes and the protein transmits signals to the podocyte actin cytoskeleton.MethodsNephron-specific TrkC knockout (TrkC-KO) and nephron-specific TrkC-overexpressing (TrkC-OE) mice were generated to dissect the role of TrkC in nephron development and maintenance.ResultsBoth TrkC-KO and TrkC-OE mice exhibited enlarged glomeruli, mesangial proliferation, basement membrane thickening, albuminuria, podocyte loss, and aspects of FSGS during aging. Igf1 receptor (Igf1R)–associated gene expression was dysregulated in TrkC-KO mouse glomeruli. Phosphoproteins associated with insulin, erb-b2 receptor tyrosine kinase (Erbb), and Toll-like receptor signaling were enriched in lysates of podocytes treated with the TrkC ligand neurotrophin-3 (Nt-3). Activation of TrkC by Nt-3 resulted in phosphorylation of the Igf1R on activating tyrosine residues in podocytes. Igf1R phosphorylation was increased in TrkC-OE mouse kidneys while it was decreased in TrkC-KO kidneys. Furthermore, TrkC expression was elevated in glomerular tissue of patients with diabetic kidney disease compared with control glomerular tissue.ConclusionsOur results show that TrkC is essential for maintaining glomerular integrity. Furthermore, TrkC modulates Igf-related signaling in podocytes. 相似文献
954.
955.
956.
957.
958.
959.
Ann Taber Youngrok Park Alana Lelo Frederik Prip Jerry Xiao Deborah L. Berry Krysta Chaldekas Jørgen Bjerggaard Jensen George Philips Jung-Sik Kim Brent T. Harris Lars Dyrskjøt Todd Waldman 《Urologic oncology》2021,39(7):438.e1-438.e9
ObjectiveImprovements to bladder cancer risk stratification guidelines are needed to better tailor post-operative surveillance and adjuvant therapy to individual patients. We previously identified STAG2 as a commonly mutated tumor suppressor gene in bladder cancer and an independent predictor of progression in NMIBC. Here we test the value of combining STAG2 immunostaining with other risk stratification biomarkers in NMIBC, and as an individual biomarker in MIBC.Materials and MethodsSTAG2 immunohistochemistry was performed on a progressor-enriched cohort of tumors from 297 patients with NMIBC, and on tumors from 406 patients with MIBC from Aarhus University Hospital in Denmark. Survival analysis was performed using Kaplan-Meier survival analysis, the log rank test, and Cox proportional hazards models.ResultsSTAG2-negative low-grade NMIBC tumors were 2.5 times less likely to progress to muscle invasion than STAG2-positive low-grade NMIBC tumors (Log-rank test, P = 0.008). In a composite group of patients with AUA intermediate and high-risk NMIBC tumors, STAG2-negative tumors were less likely to progress (Log-rank test, P = 0.02). In contrast to NMIBC, we show that STAG2 is not useful as a prognostic biomarker in MIBC.ConclusionsSTAG2 immunostaining can be used to subdivide low-grade NMIBC tumors into two groups with substantially different risks of disease progression. Furthermore, STAG2 immunostaining may be useful to enhance NMIBC risk stratification guidelines, though larger cohorts are needed to solidify this conclusion in individual risk groups. STAG2 is not useful as a biomarker in MIBC. Further study of the use of STAG2 immunostaining as a biomarker for predicting the clinical behavior in NMIBC is warranted. 相似文献
960.